Edgewise Therapeutics (EWTX) reported a Q4 net loss Monday of $0.42 per diluted share.
Analysts polled by FactSet expected a loss of $0.37.
As expected, the company did not report any revenue for the quarter ended Dec. 31. Meanwhile, operating expenses were $45.5 million for the quarter.
The clinical-stage biopharmaceutical firm said it ended Q4 with $470.2 million in cash, cash equivalents and marketable securities, which it expects to fund its current operating plan for "at least the next 12 months."
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。